Choosing not to use systemic hormones does not end the conversation about menopause symptoms. There are nonhormonal approaches, but the appropriate option depends on the symptom and the person’s health history.
Do not equate nonhormonal with harmless or over-the-counter. Some alternatives are prescription medicines with important warnings; others are behavioral approaches or products with a much less certain evidence base.
In this entry
Separate hot flashes from other concerns
A medicine used for vasomotor symptoms may not treat vaginal dryness. A lubricant may reduce friction without addressing sleep disruption. Clarify the main treatment target so the follow-up can judge something specific.
Clinicians may discuss selected nonhormonal prescription medicines, including options also used for other conditions. The relevant evidence, interactions and adverse effects differ by product. Ask whether a proposed use is approved or off-label and why it fits your history.
Fezolinetant has a defined safety workload
Veozah, the brand for fezolinetant, is a nonhormonal treatment for moderate to severe vasomotor symptoms due to menopause. The FDA added a boxed warning for rare but serious liver injury. The agency describes liver testing before treatment, monthly for the first three months and again at months six and nine.
Before starting, ask who orders the tests, where they happen, how results are reviewed and what the total cost will be. Follow current prescribing information and the clinician’s plan. Symptoms such as yellowing of the skin or eyes, dark urine or substantial new fatigue need prompt attention under that plan.
Local comfort is a separate track
Moisturizers and lubricants may help some vaginal symptoms, but persistent pain, bleeding, discharge or urinary problems need assessment. Low-dose vaginal estrogen is hormonal, even though its exposure and purpose differ from systemic therapy. It should be discussed accurately rather than placed in a nonhormonal category.
The estradiol notes explain the local-versus-systemic distinction. A history that makes systemic treatment unsuitable may call for a more specialized discussion about local treatment, not a conclusion drawn from a product list.
Put supplements through the same question test
What exact preparation was studied? For which symptom? What interactions or adverse effects are possible? A similar ingredient name does not establish that a supplement on a provider’s store page produces the same result as a studied preparation.
Tell the clinician about supplements before starting a prescription. Natural ingredients can still have pharmacologic effects, and a product bundle is not evidence that every component is necessary.
Choose a service that can support the plan
Evernow and Gennev describe nonhormonal options. Confirm whether the required monitoring and local referrals fit the service’s care model. A cheap visit is not the full cost if tests and follow-up are essential.
The cost checklist can be used for nonhormonal care too. The principle is the same: know the target, the product, the evidence, the ongoing responsibilities and the point at which the plan should be reconsidered.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.